Stocks › ABCL
AbCellera Biologics Inc.
ABCL·Nasdaq·
Canada·USD
Canada·USD$13.15
-0.63 (-4.57%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
ABCL
AbCellera Biologics Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ABCLS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of ABCL by members of U.S. Congress · 0 on record
No congressional trades in ABCL on record.
Whale Activity
Position changes in ABCL reported for 2026-06-30 by 8 tracked institutional filers
- Increased1
- New1
- Held0
- Decreased4
- Closed1
- No prior filing1
| Filer | Shares | Value | Change |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | 10.4M | $81.9M | decreased |
| BlackRock, Inc. | 3.8M | $29.9M | decreased |
| CITADEL ADVISORS LLC | 1.6M | $12.5M | increased |
| RENAISSANCE TECHNOLOGIES LLC | 990.9K | $7.8M | decreased |
| MILLENNIUM MANAGEMENT LLC | 518.6K | $4.1M | decreased |
| D. E. Shaw & Co., Inc. | 45.4K | $357K | new |
| BRANDYWINE MANAGERS, LLC | 28.5K | $224K | — |
| Point72 Asset Management | 0 | $0 | closed |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by ABCL insiders, by quarter · Form 4
Recent Insider Transactions
114 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Hayden Michael RDirector · Director | Purchase | +53.6K | $10.64 | $570K | Aug 24, 2026 | Form 4 ↗ |
| Montalbano John S.Director · Director | Purchase | +10.0K | $11.03 | $110K | Aug 18, 2026 | Form 4 ↗ |
| Booth AndrewChief Financial Officer | Purchase | +37.2K | $10.32 | $384K | Aug 14, 2026 | Form 4 ↗ |
| Hayden Michael RDirector · Director | Purchase | +46.4K | $10.37 | $481K | Aug 12, 2026 | Form 4 ↗ |
| Booth AndrewChief Financial Officer | Option exercise | +250.0K | $0.19 | $48K | Jun 3, 2026 | Form 4 ↗ |
| Montalbano John S.Director | Purchase | +20.0K | $4.77 | $95K | May 14, 2026 | Form 4 ↗ |
| Thermopylae Holdings Ltd.10% owner | Purchase | +38.0K | $3.44 | $131K | Feb 27, 2026 | Form 4 ↗ |
| Booth AndrewChief Financial Officer | Purchase | +42.6K | $3.42 | $146K | Feb 27, 2026 | Form 4 ↗ |
| Thermopylae Holdings Ltd.10% owner | Purchase | +177.5K | $3.27 | $580K | Feb 26, 2026 | Form 4 ↗ |
| Thermopylae Holdings Ltd.10% owner | Gift | −225.0K | $0.00 | $0 | Dec 18, 2025 | Form 4 ↗ |
| Montalbano John S.Director | Purchase | +50.0K | $3.57 | $179K | Nov 26, 2025 | Form 4 ↗ |
| Thermopylae Holdings Ltd.10% owner | Purchase | +343.6K | $2.16 | $742K | Mar 11, 2025 | Form 4 ↗ |
| Montalbano John S.Director | Purchase | +25.0K | $2.30 | $57K | Mar 10, 2025 | Form 4 ↗ |
| Montalbano John S.Director | Purchase | +60.0K | $2.34 | $140K | Mar 6, 2025 | Form 4 ↗ |
| Thermopylae Holdings Ltd.10% owner | Gift | −286.0K | $0.00 | $0 | Dec 4, 2024 | Form 4 ↗ |
| Hansen Carl L. G.Chief Executive Officer · Director · 10% owner | Option exercise | +56.1K | $2.70 | $152K | Nov 25, 2024 | Form 4 ↗ |
| Hansen Carl L. G.Chief Executive Officer · Director · 10% owner | Option exercise | +56.1K | $2.70 | $152K | Sep 20, 2024 | Form 4 ↗ |
| Thermopylae Holdings Ltd.10% owner | Purchase | +283.5K | $2.61 | $740K | Aug 29, 2024 | Form 4 ↗ |
| Lecault VeroniqueChief Operating Officer · Director | Option exercise | +83.3K | $0.19 | $16K | Jun 21, 2024 | Form 4 ↗ |
| Hansen Carl L. G.Chief Executive Officer · Director · 10% owner | Option exercise | +56.1K | $2.70 | $152K | May 31, 2024 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding ABCL · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| SMALLCAP World Fund Inc | 13.2M | $103.8M | 0.11% | Jun 30, 2026 |
| iShares Biotechnology ETF iShares Trust | 1.7M | $13.0M | 0.14% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1.1M | $8.3M | 0.06% | Jun 30, 2026 |
| Counterpoint Quantitative Equity ETF NORTHERN LIGHTS FUND TRUST III | 971.6K | $7.6M | 2.07% | Jun 30, 2026 |
| State Street(R) SPDR(R) Portfolio Developed World ex-US ETF SPDR INDEX SHARES FUNDS | 564.3K | $4.4M | 0.01% | Jun 30, 2026 |
| iShares Genomics Immunology and Healthcare ETF iShares Trust | 508.9K | $2.9M | 1.52% | Jul 31, 2026 |
| SMALLCAP World Fund AMERICAN FUNDS INSURANCE SERIES | 359.8K | $2.8M | 0.11% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund BlackRock Funds | 339.6K | $2.1M | 0.04% | May 29, 2026 |
| Driehaus Micro Cap Growth Fund Driehaus Mutual Funds | 246.6K | $1.9M | 0.32% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) International Small Cap ETF SPDR INDEX SHARES FUNDS | 166.0K | $1.3M | 0.15% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list ABCL's shares (CUSIP 00288U106), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Felix J. BakerSCHEDULE 13G/A · passive (13G) · 33.0M shares10.8%
May 7, 2026 · ↗ - Julian C. BakerSCHEDULE 13G/A · passive (13G) · 33.0M shares10.8%
May 7, 2026 · ↗ - Baker Bros. Advisors (GP) LLCSCHEDULE 13G/A · passive (13G) · 33.0M shares10.8%
May 7, 2026 · ↗ - Baker Bros. Advisors LPSCHEDULE 13G/A · passive (13G) · 33.0M shares10.8%
May 7, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming AbCellera Biologics Inc. as client
No lobbying filings found naming AbCellera Biologics Inc. as the client.
Government Contracts
Federal awards to AbCellera Biologics Inc. · USAspending
No federal contract awards found for AbCellera Biologics Inc..
U.S. Patents
Recent USPTO applications naming AbCellera Biologics Inc.
No USPTO patent applications found for AbCellera Biologics Inc..
Annual Financials
From ABCL's 10-K filings · XBRL
No annual XBRL figures on record for ABCL. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in ABCL's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 1.01, 8.01, 9.01Material agreement · Other eventsAug 13, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureAug 10, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsAug 7, 2026
EDGAR ↗ - 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureAug 5, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsJul 29, 2026
EDGAR ↗ - 8-K · Items 5.02, 9.01Officer / director changeJul 6, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsJun 17, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteJun 12, 2026
EDGAR ↗ - 8-K · Items 5.02, 9.01Officer / director changeJun 5, 2026
EDGAR ↗ - 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureMay 11, 2026
EDGAR ↗
About AbCellera Biologics Inc.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersVANCOUVER, British Columbia, Canada
IncorporatedA1
SEC CIK0001703057 ↗